跳转至内容
Merck

A4669

Sigma-Aldrich

阿昔洛韦

≥99% (HPLC), powder

别名:

9-[(2-羟基乙氧基)甲基]鸟嘌呤, 阿苷洛韦

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H11N5O3
CAS号:
分子量:
225.20
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥99% (HPLC)

形狀

powder

顏色

white

溶解度

H2O: 0.7 mg/mL
1 M HCl: 50 mg/mL
DMSO: 7 mg/mL

&epsilon ;(消光係數)

11.8 at 256 nm at 1 mM

抗生素活性譜

viruses

作用方式

DNA synthesis | interferes

起源

GlaxoSmithKline

SMILES 字串

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

InChI 密鑰

MKUXAQIIEYXACX-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

无环鸟苷或阿昔洛韦是一种鸟苷类似物。

應用

阿昔洛韦作为I型单纯疱疹病毒抑制剂的应用实例:
  • 作为阳性对照,通过Vero细胞毒性检测法比较蘑菇提取物的抗病毒活性
  • 在感染研究中,检测其对人背根神经节来源神经元(HD10.6)细胞的电压门控钠离子通道(VGSC)的影响
  • 检测其对人包皮成纤维细胞的干扰素刺激基因(ISG)表达诱导(Mx1和ISG15)的影响

生化/生理作用

阿昔洛韦是一种抗病毒药,在单纯疱疹病毒胸苷激酶(HSV-TK)的作用下变成三磷酸阿昔洛韦。它竞争性地抑制病毒DNA聚合酶。它对巨细胞病毒和EB(Epstein-Barr)病毒的疗效相对较弱。阿昔洛韦已被用来研究单纯疱疹病毒的潜伏机制。它也具有抗人免疫缺陷型病毒1(HIV-1)活性。

特點和優勢

该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处
这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Antiviral nanodelivery systems: current trends in acyclovir administration
Haniza H, et al.
Journal of Nanomaterials (2016)
L Z Rubsam et al.
Cancer research, 58(17), 3873-3882 (1998-09-10)
Enzyme-prodrug therapy using ganciclovir and herpes simplex virus-thymidine kinase (HSV-TK) has demonstrated excellent antitumor activity in many different types of malignant cells. Previously, we noted that ganciclovir was substantially more cytotoxic than other HSV-TK substrates. Therefore, we embarked on a
Adalbert Krawczyk et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(17), 6760-6765 (2013-04-10)
Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency
Daniel S Owers et al.
The Cochrane database of systematic reviews, 2(2), CD005133-CD005133 (2013-03-02)
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using antiviral agents has been suggested as an alternative to routine prophylaxis to prevent CMV disease. This is
Sonia Burrel et al.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 58(1), 321-324 (2013-06-05)
Herpes simplex virus type 1 (HSV-1) is a leading cause of corneal blindness. Acyclovir (ACV) constitutes the standard treatment of HSV infections including herpetic keratitis (HK). HSV resistance to ACV is mainly described in immunocompromised patients. We describe two cases

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门